These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28084618)

  • 1. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
    Bachurin SO; Bovina EV; Ustyugov AA
    Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends].
    Bachurin SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(8):77-87. PubMed ID: 28635742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular pathogenesis and development of disease-modifying drugs for Alzheimer's disease].
    Takeda M
    Seishin Shinkeigaku Zasshi; 2013; 115(1):32-40. PubMed ID: 23691792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease.
    Adlard PA; James SA; Bush AI; Masters CL
    Drugs Today (Barc); 2009 Apr; 45(4):293-304. PubMed ID: 19499094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates.
    Hroudová J; Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Aug; 134():111069. PubMed ID: 38917881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural Products in Alzheimer's Disease Therapy: Would Old Therapeutic Approaches Fix the Broken Promise of Modern Medicines?
    Habtemariam S
    Molecules; 2019 Apr; 24(8):. PubMed ID: 30999702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.
    Iqbal K; Chohan MO; Grundke-Iqbal I
    J Alzheimers Dis; 2008 Oct; 15(2):339-45. PubMed ID: 18953118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in Alzheimer's disease drug development.
    Cummings JL
    Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs.
    Ihara M; Saito S
    J Alzheimers Dis; 2020; 74(4):1013-1028. PubMed ID: 32144994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug Repositioning for Alzheimer's Disease].
    Ihara M; Saito S
    Brain Nerve; 2019 Sep; 71(9):961-970. PubMed ID: 31506398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural products against Alzheimer's disease: Pharmaco-therapeutics and biotechnological interventions.
    Dey A; Bhattacharya R; Mukherjee A; Pandey DK
    Biotechnol Adv; 2017; 35(2):178-216. PubMed ID: 28043897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs targeting Alzheimer's disease: some things old and some things new.
    Michaelis ML
    J Pharmacol Exp Ther; 2003 Mar; 304(3):897-904. PubMed ID: 12604663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradigm shift from diagnosing patients based on common symptoms to categorizing patients into subtypes with different pathogenic mechanisms to guide treatment for Alzheimer's disease.
    Shirotani K; Asai M; Iwata N
    J Biochem; 2017 Jun; 161(6):463-470. PubMed ID: 28338847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond amyloid: the future of therapeutics for Alzheimer's disease.
    Lane RF; Shineman DW; Steele JW; Lee LB; Fillit HM
    Adv Pharmacol; 2012; 64():213-71. PubMed ID: 22840749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.